^
    4d
    Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer. (PubMed, Eur J Cancer)
    Dirozalkib exhibited favorable safety, antitumor activity and pharmacokinetics in patients with advanced ALK-rearranged NSCLC. The recommended phase II dose was 500 mg/day.
    P1 data • Preclinical • Journal • First-in-human
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ALK rearrangement • ALK fusion • ROS1 rearrangement
    |
    Xuan Fei Ning (dirozalkib)
    6ms
    A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=114, Completed, Xuanzhu Biopharmaceutical Co., Ltd. | Recruiting --> Completed
    Trial completion
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • ROS1 positive • ROS1 rearrangement
    |
    Xuan Fei Ning (dirozalkib)
    8ms
    Food Effect and Mass Balance Study of XZP-3621 Tablets (clinicaltrials.gov)
    P1, N=34, Completed, Xuanzhu Biopharmaceutical Co., Ltd. | Not yet recruiting --> Completed
    Trial completion
    |
    Xuan Fei Ning (dirozalkib)
    over4years
    A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=120, Recruiting, Xuanzhu Biopharmaceutical Co., Ltd.
    Clinical • New P1 trial
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ALK rearrangement • ROS1 positive • ROS1 rearrangement
    |
    Xuan Fei Ning (dirozalkib)